NCT06985342View on ClinicalTrials.gov

Acute Migraine Treatment in the ED With Gepants

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Migraine Headaches
Interventions
DRUG

Rimegepant

Rimegepant 75 mg orally disintegrating tablet (ODT), administered as a single dose

DRUG

Zavegepant

Zavegepant 10 mg nasal spray, administered as a single dose

Trial Locations (1)

10029

RECRUITING

Mount Sinai Hospital, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT06985342 - Acute Migraine Treatment in the ED With Gepants | Biotech Hunter | Biotech Hunter